MEDTECH

CosmosID Launches Accurate and Easy Functional Microbiome Analysis with New Software Platform, CosmosID-HUB: Microbiome

CosmosID | September 27, 2021

A complete analysis of the microbiome should combine taxonomic profiling ("who is there?") with functional characterization ("what are they doing?") to discover the capabilities of an entire community of microorganisms. But research teams often require specialized training and extensive computational infrastructure to establish an in-house suite of tools for processing shotgun metagenomic data – and even with the right know-how, the processing can be both time-consuming and challenging.

CosmosID®, known for the most accurate, multi-kingdom, strain level taxonomic profiling technology, has added a functional analysis module to its popular online user-interface, renamed 'CosmosID-HUB: Microbiome'.

Now, in addition to microbiome sequencing services out of its Germantown, MD, laboratory, its industry-leading team of bioinformaticians and software developers, has unveiled a suite of new features for seamless analysis of the genomic potential of microbial communities:
  • Direct links from the platform to MetaCyc and GO terms databases.
  • Data import via direct upload, Illumina BaseSpace & automated SRA import from NCBI with analysis speeds up to 19X faster than open-source tools.
  • Find your organism or gene/pathway of interest with search functions, exportable charts & visualizations.
  • Comparative analysis software, complete with dynamic charts, graphs, and statistical significance testing.
  • Easy-to-navigate user interface OR command-line access.
  • Applicable to almost any sample type
  • Applicable to both metagenomic and metatranscriptomics data

Knowing the combined genomic potential of a microbial community is proving indispensable for practical applications of translational microbiome science, This cutting edge, accurate, easy and fast functional analysis feature is part of our ongoing mission to provide everything researchers need to complete their end-to-end microbiome analysis and lower the barrier to entry for those interested in the field.

- CosmosID CEO, Manoj Dadlani.

The updated web application is part of CosmosID's microbial genomics platform, CosmosID-HUB, which is continually expanding with various apps and modules for analyzing microbial communities and for inferring translational and actionable microbiome insights. Currently, CosmosID-HUB: Microbiome provides options for discovering antimicrobial resistance and virulence markers, microbial taxa (composition) and function whereas CosmosID-HUB: COVID-19 is a separate module for detecting the presence of COVID-19 and characterizing variants of concern/interest in both clinical and wastewater specimens. Researchers have the flexibility to access and pay for the type of analysis they require. Soon, CosmosID-HUB will include a revolutionary web application for microbiome multi-dimensional feature testing and multi-omics analysis.

In addition to strain-level resolution enabled by its curated databases of over 170,000 genomes and gene sequences, CosmosID® also offers next-generation sequencing services. To date, the company has demonstrated its best-in-class technology and won three different challenges for its detection accuracy, including both PrecisionFDA challenges as well as the Janssen/DNAnexus Mosaic 'Strain' challenge.

About CosmosID®
CosmosID® provides end-to-end solutions unlocking the microbiome. A provider of CLIA-certified & ICH-GCP compliant NGS Services and Bioinformatics Solutions, CosmosID offers a range of validated and optimized workflows for a range of applications including pharmaceutical R&D, infectious disease diagnostics, environmental testing, microbiome research, animal health, cosmetics & personal care as well as many more. CosmosID also offers independently validated, industry-leading pipelines for processing metagenomic data, yielding multi-kingdom, strain-level resolution with leading sensitivity and precision as well as functional characterization

Spotlight

DNAsequencinghascome a long way since the days of two-dimensional chromatography in the 1970s. With the advent of the anger chain termination method1 in1977, scientists gained the ability tosequenceDNAin a reliable, reproducible manner. A decade later, Applied Biosystems introduced the first automated, capillary electrophoresis (CE)-based sequencing instruments, the AB370in1987and theAB3730xl in1998, instruments that became the primary workhorse for the NIH-led and Celera-led Human Genome Projects.


Other News
INDUSTRIAL IMPACT

Portal Innovations Expands Chicago Operations Triples Space in Fulton Labs

Portal Innovations | February 03, 2022

Portal Innovations continues its momentum in Chicago by launching the second phase of its operations with the opening of 35,000 square feet of premier wet and dry lab and office space at 400 North Aberdeen in Fulton Labs. The new facility will allow Portal, a life sciences venture development engine, to grow and scale its investment in early-stage biotech companies in Chicago. Portal has tapped Patrick Flavin to serve as President of its flagship Chicago operation. With over 20 years of experience building high-performing teams and collaborations with corporate partners in several public and private life sciences companies, Patrick brings his seasoned biotech-entrepreneurial experience to navigate Portal’s portfolio expansion. Patrick was the founding Executive Director at MATTER and currently serves as a Managing Director at Portal. “I am excited to partner with Patrick as we continue to build Portal into a premier platform of investment in transformative companies with the best innovators, entrepreneurs, academic institutions, and venture capitalists. Patrick’s experience and vision are crucial for Portal to reach the next level here in Chicago.” Portal Founder and CEO John Flavin Through its “Crafted Capital” model, Portal invests seed financial funding, offers access to fully equipped wet and dry lab space, and provides management expertise to leading scientific and entrepreneurial founders. Portal is building a valuable portfolio of life sciences companies at the seed to series A investment stage for long-term value creation. Portal has partnered with Trammell Crow Company, one of the largest commercial real estate developers in the United States, to catalyze the Chicago regional life sciences ecosystem at the Fulton Labs Campus and is currently investing in and supporting companies in its existing 11,000 square feet of wet and dry lab and office space at 1375 West Fulton Street. “I am thrilled to expand our operations in Fulton Labs during a very exciting time for breakthroughs in biotech,” said Patrick Flavin. “Portal’s expansion of lab and office space will accelerate our ability to invest in, house, and support the promising life sciences companies that are emerging from the region’s top tier research institutions.” About Portal Innovations Portal Innovations is a premier venture development engine that bridges scientific ideation in life sciences, medtech, and bioinformatics through commercial proof of concept by delivering crafted capital, including seed funding, specialized equipment, lab space, and management expertise to high-potential early-stage companies.

Read More

INDUSTRIAL IMPACT

Chimeron Bio Expands Footprint in Philadelphia by Joining BioLabs at The Curtis

Chimeron Bio | January 25, 2022

Chimeron Bio, a biotechnology company pioneering a novel class of self-amplifying RNA-vaccines and therapeutics announced its plan to expand operations in the Philadelphia area and move to The Curtis, a landmark site in Center City Philadelphia under BioLabs, the leading developer and operator of life science co-working spaces in the U.S. and internationally. The move stems from Chimeron’s need for an expanded footprint to accommodate its growing R&D team and operations. The Curtis, a historical landmark has been reimagined to host first-class wet labs and is quickly becoming a hub for top-tier life science organizations in the Philadelphia area. Chimeron Bio’s move to The Curtis will solidify their position as emerging leaders in biotechnology as the company works to advance its pipeline to the clinic. “We are pleased to be joining BioLabs Philadelphia, a facility that offers unwavering support for success and growth. We expect this new facility to drive our next phase of growth by enabling our growing team to conduct cutting-edge research as we work to bring high-impact accessible RNA medicines to patients. At this new site, we look forward to continuing our trajectory of attracting premier talent and becoming a major player in Philly’s growing life science ecosystem,” Dr. Jolly Mazumdar, PhD, MBA, co-founder and CEO of Chimeron Bio About Chimeron Bio Chimeron Bio is a biotechnology company focused developing a pipeline of self-amplifying RNA medicines, both therapeutics and vaccines, designed on its proprietary ChaESAR™ delivery technology platform.

Read More

CELL AND GENE THERAPY

Dyadic Announces a NIIMBL Coronavirus Grant Under the White House’s American Rescue Plan

Dyadic International, Inc. | December 23, 2021

Dyadic International, Inc. a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve access to biologic vaccines and drugs at flexible commercial scales, announced it is the recipient of one of thirty-two project grants awarded by the National Institute for Innovation in Manufacturing Biopharmaceuticals funded through the White House’s American Rescue Plan. Under the NIIMBL grant, Dyadic will receive up to $690,000 in funding to engineer the Company’s proprietary and patented C1 thermophilic fungal protein production platform to produce two different antibodies. “We are honored to have been selected by NIIMBL to receive this grant and to further leverage Dyadic’s C1-cell protein production platform to help the nation prevent, prepare for, and respond to coronavirus and other public health threats. The grant provides us with the opportunity, among other attributes, to further demonstrate to academia, industry, and governmental agencies the rapid speed at which we can develop stable C1 expressing cell lines to produce antibodies as compared to traditional cell lines, such as Chinese Hamster Ovary cells. We look forward to moving this project forward in the new year,” Mark Emalfarb, Dyadic’s President and Chief Executive Officer NIIMBL members include large and small companies, academic institutions, non-profits, and federal agency partners who are well-equipped to significantly strengthen the nation’s preparedness and response to public health crises. Through the ARP funding, NIIMBL has selected projects that will Provide testbeds for process development, for next generation manufacturing approaches, and for drug product manufacturing approaches that provide access to industrially relevant equipment and facilities for pre-competitive manufacturing innovation Support the development of significantly improved methods for vaccine production, quality, and distribution, including mRNA and other vaccine platforms Demonstrate rapid scaling for production of coronavirus antigens and medical countermeasures for variants of concern Train a diverse biopharmaceutical manufacturing workforce Demonstrate the concept of mobile Good Manufacturing Practices capabilities to support mRNA vaccine and gene therapy production Dyadic’s project grant is intended to benchmark the speed that the C1 manufacturing platform will have when compared to current state of the art methods, which could lead to a rapid ability to produce medical countermeasures and vaccines in response to future pandemics. About NIIMBL The National Institute for Innovation in Manufacturing Biopharmaceuticals is a public-private partnership whose mission is to accelerate biopharmaceutical innovation, support the development of standards that enable more efficient and rapid manufacturing capabilities, and educate and train a world-leading biopharmaceutical manufacturing workforce, fundamentally advancing U.S. competitiveness in this industry. NIIMBL is part of Manufacturing USA®, a diverse network of federally-sponsored manufacturing innovation institutes, and is funded through a cooperative agreement with the National Institute of Standards and Technology in the U.S. Department of Commerce with significant additional support from its members. Visit NIIMBL.org to view a summary of these projects and to learn more about NIIMBL. About Dyadic International, Inc. Dyadic International, Inc. is a global biotechnology company that is developing what it believes will be a potentially significant biopharmaceutical gene expression platform based on the fungus Thermothelomyces heterothallica, named C1. The C1 microorganism, which enables the development and large-scale manufacture of low-cost proteins, has the potential to be further developed into a safe and efficient expression system that may help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales.

Read More

INDUSTRIAL IMPACT

Harbour BioMed Announces Approval for Phase I Trial of B7H4x4-1BB Bispecific Antibody in Australia

Harbour BioMed | February 28, 2022

Harbour BioMed announced that, it has been approved by the Institutional Review Boards to commence phase I trial of its B7H4x4-1BB bispecific antibody in Australia. This study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity of HBM7008 in patients with solid tumors. HBM7008 is generated from our unique and innovative HBICE® platform. It targets Tumor Associated Antigen mediated crosslinking T cell activation through 4-1BB. B7H4 is overexpressed on a variety of solid malignancies, including breast, ovarian, endometrial and non-small cell lung cancers. With its crosslinking dependent specificity on tumors and potent immune modulation activity, HBM7008 has shown excellent safety profile with strong anti-tumor efficacy in the pre-clinical study, including completed response observed in mouse tumor model. "4-1BB is one of the most promising anti-tumor immune targets, providing new solutions for tumor treatment. Based on preclinical study data, we are highly confident in B7H4x4-1BB bispecific antibody. We will efficiently promote this clinical study to provide an novel, effective and safe treatment for patients, so that more tumor patients can benefit from the innovative therapeutic." Dr. Xiaoxiang Chen, Chief Development Officer of Harbour BioMed About HBM7008 HBM7008 is a bispecific antibody targeting Tumor Associated Antigen B7H4x4-1BB that not only displays high potency in the T cell co-stimulation and tumor growth inhibition, and potentially may also translate to better safety due to its strict dependency of TAA-mediated crosslinking T cell activation. HBM7008 is one of the fully human bispecific antibodies developed from the HBICE® platform of the Company. It is the only bispecific antibody against these two targets globally. Its unique specificity on tumors and immune modulation activity makes it a promising therapeutics in PD-L1 negative or PD-1/PD-L1 resistant patients. It also has the potential to avoid 4-1BB liver toxicity risk observed in other products with the benefit of its innovative biology mechanisms and bispecific design. About Harbour BioMed Harbour BioMed is a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immunology and oncology. The Company is building its robust portfolio and differentiated pipeline through internal R&D capability, collaborations with co-discovery and co-development partners and select acquisitions.

Read More

Spotlight

DNAsequencinghascome a long way since the days of two-dimensional chromatography in the 1970s. With the advent of the anger chain termination method1 in1977, scientists gained the ability tosequenceDNAin a reliable, reproducible manner. A decade later, Applied Biosystems introduced the first automated, capillary electrophoresis (CE)-based sequencing instruments, the AB370in1987and theAB3730xl in1998, instruments that became the primary workhorse for the NIH-led and Celera-led Human Genome Projects.

Resources